Adrenoleukodystrophy secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 6: Line 6:


==Overview==
==Overview==
The objective of secondary prevention in adrenoleukodystrophy is to diagnose it early, preferably before neurological symptoms appear so as to prevent nerve cell damage from occurring, initiating timely adrenal steroid replacement therapy following detection of adrenal insufficiency, and for providing allogeneic hematopoietic stem cell transplantation (HSCT) as a means of treating cerebral ALD. In February 2016, adrenoleukodystrophy was added to the Recommended Uniform Screening Panel (RUSP) in the USA, which is the federal list of all genetic diseases recommended for state newborn screening programs.


==Secondary Prevention==
==Secondary Prevention==
The objective of secondary prevention in adrenoleukodystrophy is to '''diagnose''' it early, preferably before neurological symptoms appear so as to prevent nerve cell damage from occurring, initiating timely adrenal steroid replacement therapy following detection of adrenal insufficiency, and for providing allogeneic hematopoietic stem cell transplantation (HSCT) as a means of treating cerebral ALD. In February 2016, adrenoleukodystrophy was added to the Recommended Uniform Screening Panel (RUSP) in the USA<ref name="pmid273370302">{{cite journal| author=Kemper AR, Brosco J, Comeau AM, Green NS, Grosse SD, Jones E | display-authors=etal| title=Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. | journal=Genet Med | year= 2017 | volume= 19 | issue= 1 | pages= 121-126 | pmid=27337030 | doi=10.1038/gim.2016.68 | pmc=5182180 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27337030  }}</ref>, which is the federal list of all genetic diseases recommended for state newborn screening programs.


==References==
==References==

Latest revision as of 15:13, 29 June 2020

Adrenoleukodystrophy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenoleukodystrophy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Adrenoleukodystrophy secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenoleukodystrophy secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenoleukodystrophy secondary prevention

CDC on Adrenoleukodystrophy secondary prevention

Adrenoleukodystrophy secondary prevention in the news

Blogs on Adrenoleukodystrophy secondary prevention

Directions to Hospitals Treating Adrenoleukodystrophy

Risk calculators and risk factors for Adrenoleukodystrophy secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

The objective of secondary prevention in adrenoleukodystrophy is to diagnose it early, preferably before neurological symptoms appear so as to prevent nerve cell damage from occurring, initiating timely adrenal steroid replacement therapy following detection of adrenal insufficiency, and for providing allogeneic hematopoietic stem cell transplantation (HSCT) as a means of treating cerebral ALD. In February 2016, adrenoleukodystrophy was added to the Recommended Uniform Screening Panel (RUSP) in the USA, which is the federal list of all genetic diseases recommended for state newborn screening programs.

Secondary Prevention

The objective of secondary prevention in adrenoleukodystrophy is to diagnose it early, preferably before neurological symptoms appear so as to prevent nerve cell damage from occurring, initiating timely adrenal steroid replacement therapy following detection of adrenal insufficiency, and for providing allogeneic hematopoietic stem cell transplantation (HSCT) as a means of treating cerebral ALD. In February 2016, adrenoleukodystrophy was added to the Recommended Uniform Screening Panel (RUSP) in the USA[1], which is the federal list of all genetic diseases recommended for state newborn screening programs.

References

  1. Kemper AR, Brosco J, Comeau AM, Green NS, Grosse SD, Jones E; et al. (2017). "Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation". Genet Med. 19 (1): 121–126. doi:10.1038/gim.2016.68. PMC 5182180. PMID 27337030.

Template:WH Template:WS